09/26/2026
🌊 The next wave of obesity therapeutics is approaching. Are you ready to interpret the evidence?
In the final installment of Riding the Waves of Obesity Science, explore emerging, investigational amylin-based therapies and the clinical trial signals shaping the field.
Learn how to look beyond the headlines and evaluate emerging evidence through the lenses of efficacy, tolerability, and individual patient response.
🎥 Watch now: https://cmeo.me/SN-317
The obesity pipeline is moving faster than the evidence can be absorbed. A new class of amylin-based agents — investigational therapies now advancing through phase 2 and phase 3 trials with several studied both on their...